To receive full access to Campaign's content including: Unrestricted access to all The Information and The Knowledge content Access to Campaign's in-depth features and coveted reports including ...

To receive full access to Campaign's content including: Unrestricted access to all The Information and The Knowledge content Access to Campaign's in-depth features and coveted reports including ...

Paul Shannon remembers enjoying an espresso on a spring morning in the old walled Italian city of Bergamo during one of his ...

SmithKline Beecham - now GlaxoSmithKline - issued a statement ... which was ordered to pay legal costs of £40,000 plus VAT, said of Ribena ToothKind: 'The product has the support of over 1,200 ...

In this article, we are going to take a look at where GSK plc (NYSE:GSK) stands against the other pharmaceutical stocks. Almost no other industry goes as far as the phrase "defensive" as the ...

GSK Plc is a long-term underperformer among Europe’s Big Pharma stocks. And with key drug patents set to expire and vaccine sales falling, some market participants say it may draw in activist ...

GSK's revenue and EPS exceeded my expectations and those of analysts, thanks to the strong performance of its oncology and HIV franchises. So, Ojjaara/Omjjara sales amounted to $150 million in the ...

All the latest news, trends, and developments, for up to 5 users. Exclusive interviews from leading entrepreneurs, FTSE 350 CEOs, thought leaders. MT Classroom - giving you an academic grounding ...

GSK plc GSK reported fourth-quarter 2024 core earnings of 59 cents per American depositary share (ADS), which beat the Zacks Consensus Estimate of 53 cents. Core earnings declined 20% year over ...

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. Hedge fund Citadel has made a £305mn bet against drugmaker GSK, the biggest short position against the ...